SEC Comment Letter for SCYNEXIS (SCYX) — May 6, 2026
SCYNEXIS INC
Date: May 6, 2026 · CIK: 0001178253 · Accession: 0000000000-26-004629
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295493
Letter
Re: SCYNEXIS, Inc. Registration Statement on Form S-3 Filed May 01, 2026 File No. 333-295493 Dear David Angulo M.D.:
May 6, 2026
David Angulo, M.D. Chief Executive Officer SCYNEXIS, Inc. 1 Evertrust Plaza, 13th Floor Jersey City, NJ 07302-6548
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Matthew Hemington, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 6, 2026 David Angulo, M.D. Chief Executive Officer SCYNEXIS, Inc. 1 Evertrust Plaza, 13th Floor Jersey City, NJ 07302-6548 Re: SCYNEXIS, Inc. Registration Statement on Form S-3 Filed May 01, 2026 File No. 333-295493 Dear David Angulo M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew Hemington, Esq. </TEXT> </DOCUMENT>